Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 7/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24310740 | 0.98 | HDAC4 (0.62) | HDAC4LMNAALDH1A1GAAHTT | |
| SCHEMBL1626870 | 0.88 | HDAC4 (0.50) | HDAC4LMNAALDH1A1GAAHTT | |
| SCHEMBL31382033 | 0.88 | HDAC4 (0.50) | HDAC4LMNAALDH1A1GAAHTT | |
| SCHEMBL16112459 | 0.87 | HDAC4 (0.66) | HDAC4LMNAALDH1A1GAAHTT | |
| SCHEMBL16132680 | 0.86 | HDAC4 (0.69) | HDAC4 | |
| SCHEMBL16132904 | 0.84 | HDAC4 (0.68) | HDAC4 | |
| SCHEMBL30683848 | 0.80 | L3MBTL1 (0.54) | HDAC4LMNAALDH1A1HTT | |
| SCHEMBL7457587 | 0.80 | L3MBTL1 (0.54) | HDAC4LMNAALDH1A1HTT | |
| SCHEMBL31382181 | 0.79 | TSHR (0.49) | HDAC4TSHR | |
| SCHEMBL3585645 | 0.79 | TSHR (0.49) | HDAC4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7419999-B2 | Gamma lactams as prostaglandin agonists and use thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2008-09-02 | — | — | US | disclosed |
| US-20050288357-A1 | Gamma lactams as prostaglandin agonists and use thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288357-A1 | Gamma lactams as prostaglandin agonists and use thereof | PGF, HPGDS, PTGIS | HDAC4 2088/4885LMNA 1060/4885ALDH1A1 1403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.